or Try an Advanced Search...

    Cancer Immunotherapy Product Stocks List

    Symbol Grade Name % Change
    IOVA D Iovance Biotherapeutics, Inc. -7.12
    MBIO F Mustang Bio, Inc. -4.82
    ADAP F Adaptimmune Therapeutics plc -2.91
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Cancer Cancer Immunotherapy Cancer Treatment Immunotherapy Immunotherapy Products Medicine Adoptive Cell Transfer Breast And Lung Cancer Cancer Cell Clinical Medicine Immune System Melanoma Solid Tumors Virotherapy Acid Amino Acids Antineoplastic Drugs Cell Therapy Cellectis

    Related ETFs - A few ETFs which own one or more of the above listed Cancer Immunotherapy Product stocks.

    Symbol Grade Name Weight
    IDNA C iShares Genomics Immunology and Healthcare ETF 2.87
    WDNA F WisdomTree BioRevolution Fund 2.39
    BBP C BioShares Biotechnology Products Fund 1.73
    CNCR D Loncar Cancer Immunotherapy ETF 1.38
    XBI C SPDR S&P Biotech ETF 1.15
    View all Cancer Immunotherapy Product ETFs...
    Compare ETFs
    Compare BBP to CNCR Compare IDNA to CNCR Compare IDNA to XBI

        Cancer Immunotherapy Product Stocks Recent News

        Date Stock Title
        Nov 13 ADAP Adaptimmune GAAP EPS of -$0.01 beats by $0.07, revenue of $40.9M beats by $20.41M
        Nov 13 ADAP Adaptimmune to engage in restructuring; 33% headcount reduction
        Nov 13 ADAP Adaptimmune Reports Q3 2024 Financial and Business Updates
        Nov 13 ADAP Adaptimmune reports positive data in mid-stage trial of its sarcoma treatment
        Nov 13 ADAP Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
        Nov 13 ADAP Earnings Scheduled For November 13, 2024
        Nov 12 ADAP Adaptimmune Q3 2024 Earnings Preview
        Nov 12 IOVA Iovance Biotherapeutics Third Quarter 2024 Earnings: Beats Expectations
        Nov 12 MBIO Mustang Bio Receives Positive Listing Determination from Nasdaq
        Nov 11 IOVA Iovance Biotherapeutics Q3: A Beat, But A Selloff - Now A Buy Opportunity
        Nov 9 IOVA Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year
        Nov 8 IOVA IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line
        Nov 8 IOVA Iovance Biotherapeutics Inc (IOVA) Q3 2024 Earnings Call Highlights: Surpassing Revenue ...
        Nov 8 MBIO Mustang Bio’s MB-108 receives FDA orphan drug status for glioma treatment
        Nov 8 IOVA Iovance Biotherapeutics, Inc. (IOVA) Q3 2024 Earnings Call Transcript
        Nov 7 IOVA Iovance falls 12% despite Q3 beats; reaffirms 2024 revenue guidance
        Nov 7 IOVA Iovance Biotherapeutics (IOVA) Reports Q3 Loss, Tops Revenue Estimates
        Nov 7 IOVA Iovance Biotherapeutics: Q3 Earnings Snapshot
        Nov 7 IOVA Iovance Biotherapeutics GAAP EPS of -$0.28 beats by $0.02, revenue of $58.6M beats by $4.78M
        Nov 7 IOVA Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Third Quarter and Year to Date 2024
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Cancer Cancer Immunotherapy Cancer Treatment Immunotherapy Immunotherapy Products Medicine Adoptive Cell Transfer Breast And Lung Cancer Cancer Cell Clinical Medicine Immune System Melanoma Solid Tumors Virotherapy Acid Amino Acids Antineoplastic Drugs Cell Therapy Cellectis
        Cancer Immunotherapy Product

        Cancer immunotherapy is a type of treatment that uses the body’s own immune system to fight cancer. It works by stimulating the immune system to recognize and attack cancer cells. Immunotherapy products are drugs or other treatments that are designed to boost the body’s natural immune response to cancer. These products can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy.

        Browse All Tags